{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:11Z","timestamp":1790717171705,"version":"4.1.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>There is thought to be an association between hidradenitis suppurativa (HS) and autoimmune diseases. This retrospective longitudinal cohort study looked to identify whether certain autoimmune diseases or autoantibody specificities are more closely associated with HS than others and whether such associations are related to the severity of HS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were identified using the SlicerDicer search tool in Epic from 1 January 2010 to 15 August 2020. Search criteria included HS diagnosis by ICD-10 code (L73.2) and at least one visit to the dermatology department. Charts were reviewed to determine HS disease severity, treatment modalities, presence of autoimmune disease and autoantibody positivity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six hundred and twenty-seven patients were identified. Most patients were female (75.3%) and had obese BMIs (71.1%), but there were no significant demographic differences between HS patients with and without autoimmune diseases. One hundred and one (16.1%) patients in the total cohort had at least one autoimmune disease, most commonly thyroid disease, lupus, psoriasis and IBD. Two hundred and twelve patients were also tested for the presence of autoantibodies. The most common positive autoantibody, found in 54 patients (28.4%), was ANA. Fifty-four patients with more severe HS disease manifestations required biologic medications to treat their HS. Neither HS severity nor biologic treatment was associated with presence of autoimmune disease or positive autoantibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a large cohort of patients with HS followed longitudinally, autoimmune disorders (especially lupus, psoriasis and IBD) and presence of autoantibodies were more commonly observed than expected in the normal population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkab108","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T19:35:23Z","timestamp":1640633723000},"source":"Crossref","is-referenced-by-count":8,"title":["Association of hidradenitis suppurativa with autoimmune disease and autoantibodies"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-8960","authenticated-orcid":false,"given":"Yael","family":"Ross","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Ballou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"2022050607271916700_rkab108-B1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N Engl J Med"},{"key":"2022050607271916700_rkab108-B2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.7861\/clinmedicine.16-1-70","article-title":"Hidradenitis suppurativa: an update","volume":"16","author":"Ingram","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"2022050607271916700_rkab108-B3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2022050607271916700_rkab108-B4","first-page":"17","article-title":"Hidradenitis suppurativa: causes, features and current treatments","volume":"11","author":"Vinkel","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"2022050607271916700_rkab108-B5","doi-asserted-by":"crossref","first-page":"e13003","DOI":"10.1111\/dth.13003","article-title":"Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy","volume":"32","author":"Vural","year":"2019","journal-title":"Dermatol Ther"},{"key":"2022050607271916700_rkab108-B6","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jaad.2020.04.009","article-title":"Emerging medical treatments for hidradenitis suppurativa","volume":"83","author":"Lyons","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2022050607271916700_rkab108-B7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jid.2020.06.019","article-title":"A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance","volume":"141","author":"Frew","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2022050607271916700_rkab108-B8","doi-asserted-by":"crossref","first-page":"e0186","DOI":"10.1097\/MD.0000000000010186","article-title":"Hidradenitis suppurativa associated with systemic lupus erythematosus","volume":"97","author":"Ben David","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022050607271916700_rkab108-B9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"2022050607271916700_rkab108-B10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","article-title":"Long-term successful adalimumab therapy in severe hidradenitis suppurativa","volume":"145","author":"Blanco","year":"2009","journal-title":"Arch Dermatol"},{"key":"2022050607271916700_rkab108-B11","doi-asserted-by":"crossref","first-page":"18558","DOI":"10.5070\/D3196018558","article-title":"Diseases associated with hidradenitis suppurativa: part 2 of a series on hidradenitis","volume":"19","author":"Scheinfeld","year":"2013","journal-title":"Dermatol Online J"},{"key":"2022050607271916700_rkab108-B12","first-page":"62","article-title":"Hidradenitis suppurativa is an autoinflammatory keratinization disease: a review of the clinical, histologic and molecular evidence","volume":"1","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol Int"},{"key":"2022050607271916700_rkab108-B13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"key":"2022050607271916700_rkab108-B14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/1756-185X.13312","article-title":"Prevalence of antinuclear antibodies in hidradenitis suppurativa","volume":"21","author":"Mulani","year":"2018","journal-title":"Int J Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkab108\/41937747\/rkab108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/2\/rkab108\/43578333\/rkab108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/6\/2\/rkab108\/43578333\/rkab108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:27:47Z","timestamp":1651822067000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkab108\/6484658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkab108","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022]]},"published":{"date-parts":[[2021,12,27]]},"article-number":"rkab108"}}